Diabetes Care Devices Market Size & Share Analysis - Growth Trends And Forecast (2025 - 2030)

Global Diabetes Care Devices Market Trends and Insights

Rapid Reimbursement Expansion for CGM Worldwide

The expansion of insurance coverage for continuous glucose monitoring (CGM) systems is fundamentally reshaping market dynamics, with a 1.7% contribution to the overall CAGR forecast. In a significant development, New Zealand announced funding for CGMs and expanded access to insulin pumps effective October 2024, with expectations of over 12,000 people accessing funded CGMs in the first year^[1] . In February 2024, Canada^{[2]Pharmac. "Decision to fund continuous glucose monitors, insulin pumps and insulin pump consumables." August 29, 2024. www.pharmac.govt.nz Health Canada. "Universal Access to Diabetes Medications, and Diabetes Device Fund for Devices and Supplies." February 29, 2024. www.canada.ca} introduced Bill C-64 to provide universal coverage for diabetes medications and establish a dedicated fund for diabetes devices and supplies, addressing the financial burden for approximately 3.7 million Canadians with diabetes. The reimbursement landscape is shifting from covering only high-risk patients to broader populations, with private insurers following government initiatives to expand coverage criteria, creating a virtuous cycle of increased adoption, improved outcomes, and further reimbursement expansion

Increasing Global Prevalence of Diabetes and Associated Risk Factors

The alarming rise in diabetes prevalence is driving market growth with a 1.4% contribution to the overall CAGR forecast. According to a BMJ study, the global age-standardized prevalence of type 1 diabetes increased from 400 to 514 per 100,000 population between 1990 and 2019, while mortality decreased from 4.74 to 3.54 per 100,000, indicating longer lifespans for diabetic patients requiring continuous management. This epidemiological shift is creating sustained demand for diabetes devices across all segments. The Western Sydney Diabetes initiative reported diabetes rates exceeding 13% among adults in the region, with an economic burden of USD 1.8 billion annually, highlighting the financial imperative for effective management solutions. The convergence of aging populations, increasing obesity rates, and sedentary lifestyles is accelerating diabetes incidence worldwide, with particularly rapid growth in emerging economies where changing dietary patterns and urbanization are contributing factors.

Advancements in Technology

Technological innovation is revolutionizing diabetes management, contributing 1.0% to the overall CAGR forecast. The integration of artificial intelligence with continuous glucose monitoring is enabling predictive capabilities, with systems like Roche's Accu-Chek SmartGuide providing glucose level predictions from 30 minutes to two hours ahead, allowing proactive management of potential hypoglycemic events. Non-invasive monitoring technologies are advancing rapidly, with researchers at the University of Waterloo developing a wearable device using miniaturized radar technology that fits inside a smartwatch and tracks glucose levels without skin contact. Closed-loop artificial pancreas systems are automating insulin delivery, with neural-network artificial pancreas (NAP) technology demonstrating performance comparable to traditional algorithms while requiring significantly less processing time, making it suitable for devices with limited computational resources.

Increased Government and Private Investments

Strategic investments in diabetes technology are accelerating innovation and market expansion, contributing 0.8% to the overall CAGR forecast. The FY 2025 President's Budget for the Indian Health Service (IHS) proposes USD 8.2 billion in total funding, including USD 260 million specifically allocated for the Special Diabetes Program for Indians, aimed at reducing diabetes prevalence among American Indian and Alaska Native populations ^{[3]Tso, Roselyn. "Testimony from Roselyn Tso, Director, Indian Health Service on FY 2025 President's Budget Request." U.S. Department of Health and Human Services, May 8, 2024. www.hhs.gov}. In Canada, the federal government is establishing a long-awaited diabetes device fund to enhance access to innovative diabetes management technologies, responding to growing public support for government investment in research and cures. The European Commission's Horizon Europe Work Programme for 2025 is allocating significant funding for health research and innovation, with specific focus on improving healthcare systems and developing innovative health technologies for non-communicable diseases including diabetes. These investments are not only advancing technological capabilities but also expanding market access by reducing cost barriers and supporting infrastructure development.

High Cost of Devices

Premium CGM annualized costs hover near USD 3,800 for flagship brands before insurance, while lower-priced flash glucose monitors cost closer to USD 2,300. These figures, drawn from publicly available company catalog pricing, create a bifurcated market in which reimbursement status largely dictates adoption. Executives should recognize that in low-income regions even a USD 500 annual out-of-pocket burden can depress uptake, so localized manufacturing or subscription-based financing may prove effective. The takeaway for strategy teams is that pricing elasticity varies not only by per-capita income but also by cultural perceptions of preventive care; for instance, some emerging markets accept higher spending on chronic-disease devices if bundled telehealth support is included. 

Less Awareness About Device Usage in Remote and Underdeveloped Regions

Recent surveys indicate that fewer than 15 % of primary care physicians in certain Asia-Pacific districts feel fully confident in prescribing advanced diabetes devices. While that statistic emerges from regional conference proceedings rather than peer-reviewed journals, it still signals a bottleneck in the commercial funnel. Device manufacturers that build clinician-focused e-learning modules can shrink that knowledge gap and create brand loyalty ahead of competitors. A pertinent inference for executives is that educational infrastructure can serve as a market-entry wedge, often yielding a lower customer-acquisition cost than traditional direct-to-consumer advertising. 

Segment Analysis

By Device Type: Monitoring Technologies Drive Market Evolution

The monitoring devices segment commands a dominant 65.01% market share in 2024, reflecting its critical role in diabetes management across all patient populations. Continuous glucose monitoring (CGM) systems are revolutionizing diabetes care through real-time data provision and integration with automated insulin delivery systems, fundamentally changing treatment paradigms. A study published in the Journal of Diabetes Science and Technology found that CGM use is associated with lower HbA1c levels and improved outcomes, though access disparities persist by race and socioeconomic status. The management devices segment, encompassing insulin pumps, pens, and syringes, is projected to grow at a faster rate of 8.07% CAGR from 2025-2030, driven by innovations in automated insulin delivery systems and smart insulin pens.

Technological convergence is reshaping the competitive landscape, with integration between monitoring and management devices creating comprehensive diabetes management ecosystems. The emergence of hybrid closed-loop systems that combine CGM data with automated insulin delivery represents a significant advancement, with studies showing improvements in time-in-range metrics and quality of life for users. A clinical trial of the Omnipod 5 automated insulin delivery system in adults with type 2 diabetes showed a reduction in hemoglobin A1c from 8.2% to 7.4% after 13 weeks, indicating improved glycemic control. The development of non-invasive glucose monitoring technologies, including optical and electromagnetic sensors, promises to further transform the market by addressing patient discomfort associated with traditional monitoring methods.

Note: Segment shares of all individual segments available upon report purchase

By Patient Type: Type-2 Diabetes Dominates and Drives Growth

Type-2 diabetes represents the largest patient segment with an overwhelming 88.35% market share in 2024, while simultaneously exhibiting the fastest growth trajectory at 9.07% CAGR through 2030. This dual dominance reflects the global epidemic of type-2 diabetes, driven by increasing obesity rates, sedentary lifestyles, and aging populations. The management of type-2 diabetes is evolving beyond traditional approaches, with continuous glucose monitoring (CGM) increasingly recognized as valuable for this patient population. Stanford Medicine researchers have developed an AI-based algorithm that utilizes data from continuous blood glucose monitors to identify subtypes of Type 2 diabetes with approximately 90% accuracy, enabling more personalized treatment approaches.

The rise of GLP-1 receptor agonists is creating new dynamics in the type-2 diabetes devices market, with increased demand for glucose monitoring among patients using these medications. A study published in the Journal of Shoulder and Elbow Surgery found that GLP-1 users have a higher likelihood of developing adhesive capsulitis (odds ratio = 1.28), indicating a need for comprehensive monitoring during treatment. Type-1 diabetes and gestational diabetes segments, though smaller, are driving innovation in specialized devices tailored to their unique needs. The development of hybrid closed-loop systems for pediatric type-1 diabetes patients has shown significant improvements in glycemic control, with a study reporting a 0.4% reduction in HbA1c and an 8.4 percentage point increase in time spent in the target glucose range compared to sensor-augmented pump therapy.

By End-user: Home-care Settings Gain Momentum

Hospitals & Clinics currently lead the end-user segment with a 55.1% market share in 2024, benefiting from established infrastructure and specialized diabetes care teams. However, Home-care Settings are experiencing faster growth at 7.89% CAGR from 2025-2030, reflecting the paradigm shift toward patient-centered, remote diabetes management. This transition is accelerated by advancements in telehealth and connected diabetes devices that enable effective remote monitoring and intervention. In a Stanford Medicine study, an AI-powered dashboard that analyzed CGM data to help diabetes educators identify patients needing support raised the proportion achieving optimal A1c after one year to 64%, up from 28% in prior cohorts.

The integration of artificial intelligence with home diabetes management is creating new possibilities for personalized care. AI algorithms can predict glucose levels up to 30 minutes in advance, enabling proactive management and reducing the risk of severe glycemic events. Ambulatory Surgical Centers represent a smaller but growing segment, particularly for procedures related to insulin pump implantation and management of diabetes complications. The COVID-19 pandemic accelerated the shift toward home-based care, with patients and providers recognizing the benefits of remote monitoring and telehealth consultations for routine diabetes management. This trend is likely to persist and expand as technologies improve and reimbursement policies adapt to support home-based care models, fundamentally reshaping the end-user landscape for diabetes devices.

Note: Segment shares of all individual segments available upon report purchase

Geography Analysis

North America maintains a 40.71 % share in 2024, partially owing to Medicare reimbursement and a high density of device-trained endocrinologists. In 2024, the CDC recorded 29.7 million diagnosed and 8.7 million undiagnosed cases of diabetes in the United States. This sizable undiagnosed cohort provides a latent expansion pool that device makers can target via screening initiatives tied to retail pharmacies. Yet mounting pressure from employers and government payers to reduce healthcare spending suggests future price compression for premium platforms, nudging manufacturers toward value-based-care contracts. 

Asia-Pacific posts the fastest growth at 8.19 % CAGR through 2030, driven by urbanization and the world's highest absolute number of diabetes cases. International Diabetes Federation estimates place the region's share above 60 % of global prevalence. Manufacturing executives often overlook that Asia-Pacific also boasts some of the world's most digitally engaged populations, so smartphone-tethered CGM models may leapfrog earlier Bluetooth-only variants. Consequently, suppliers that embed local language AI coaching into their apps stand to win disproportionately high market share. 

Europe sustains a stable presence thanks to universal health systems and aging demographics. The region's regulatory environment, guided by the European Medicines Agency, traditionally demands longer trial follow-ups than the FDA, which can delay commercialization. The recent Abbott–Dexcom patent truce removes a legal overhang that previously cast uncertainty on procurement timelines, giving hospital buyers clearer visibility into multi-year supply contracts. An astute reading of the situation suggests that European buyers will now leverage the presence of two legally unencumbered suppliers to negotiate bulk-purchase discounts, compressing average selling prices but potentially boosting unit volumes.